LinkedIn Profile

Access Vertex Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:vrtx 6866 Apr 14th, 2024 12:00AM Vertex Pharmaceuticals 344K 5391 Open Apr 13th, 2024 11:53PM Apr 13th, 2024 11:53PM Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards. Open cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus Open Vertex Pharmaceuticals Inc. Boston MA US 02210 Vertex Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:vrtx 6866 Apr 13th, 2024 12:00AM Vertex Pharmaceuticals 344K 5393 Open Apr 12th, 2024 11:44PM Apr 13th, 2024 12:18PM Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards. Open cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus Open Vertex Pharmaceuticals Inc. Boston MA US 02210 Vertex Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:vrtx 6866 Apr 12th, 2024 12:00AM Vertex Pharmaceuticals 344K 5393 Open Apr 11th, 2024 11:52PM Apr 12th, 2024 09:14AM Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards. Open cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus Open Vertex Pharmaceuticals Inc. Boston MA US 02210 Vertex Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:vrtx 6866 Apr 11th, 2024 12:00AM Vertex Pharmaceuticals 344K 5398 Open Apr 11th, 2024 12:45AM Apr 11th, 2024 11:59AM Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards. Open cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus Open Vertex Pharmaceuticals Inc. Boston MA US 02210 Vertex Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:vrtx 6866 Apr 10th, 2024 12:00AM Vertex Pharmaceuticals 343K 5401 Open Apr 9th, 2024 11:52PM Apr 10th, 2024 06:06PM Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards. Open cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus Open Vertex Pharmaceuticals Inc. Boston MA US 02210 Vertex Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:vrtx 6866 Apr 9th, 2024 12:00AM Vertex Pharmaceuticals 343K 5401 Open Apr 9th, 2024 12:03AM Apr 9th, 2024 10:48AM Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards. Open cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus Open Vertex Pharmaceuticals Inc. Boston MA US 02210 Vertex Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:vrtx 6866 Apr 8th, 2024 12:00AM Vertex Pharmaceuticals 343K 5398 Open Apr 8th, 2024 12:53AM Apr 8th, 2024 07:44PM Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards. Open cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus Open Vertex Pharmaceuticals Inc. Boston MA US 02210 Vertex Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:vrtx 6866 Apr 7th, 2024 12:00AM Vertex Pharmaceuticals 342K 5400 Open Apr 6th, 2024 11:58PM Apr 6th, 2024 11:58PM Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards. Open cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus Open Vertex Pharmaceuticals Inc. Boston MA US 02210 Vertex Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:vrtx 6866 Apr 6th, 2024 12:00AM Vertex Pharmaceuticals 342K 5399 Open Apr 5th, 2024 11:58PM Apr 5th, 2024 11:58PM Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards. Open cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus Open Vertex Pharmaceuticals Inc. Boston MA US 02210 Vertex Pharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:vrtx 6866 Apr 5th, 2024 12:00AM Vertex Pharmaceuticals 342K 5406 Open Apr 5th, 2024 01:01AM Apr 5th, 2024 01:01AM Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards. Open cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus Open Vertex Pharmaceuticals Inc. Boston MA US 02210 Vertex Pharmaceuticals Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.